In situ gelling polymers in ocular drug delivery systems: A review

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 26, Issue 1, 2009, Pages 85-118

  Mundada, Atish S ^a   Avari, Jasmine G ^a  

^a RTM NAGPUR UNIVERSITY   (India)

Author keywords

Controlled drug release; In situ gelling; Ocular drug delivery

Indexed keywords

AGENTS ACTING ON THE EYE; ALGINIC ACID; CARBOMER; CARRAGEENAN; CELLACEFATE; CELLULOSE; CHITOSAN; CIPROFLOXACIN; GELLAN; GELLING AGENT; GELRITE; INDOMETACIN; LATEX; METHYLCELLULOSE; OFLOXACIN; PEFLOXACIN MESILATE; PILOCARPINE; POLOXAMER; POLY(N ISOPROPYLACRYLAMIDE); POLYACRYLAMIDE; POLYACRYLIC ACID; POLYMER; PSEUDOLATEX; PUERARIN; TIMOLOL MALEATE; UNCLASSIFIED DRUG; XYLOGLUCAN;

CONJUNCTIVITIS; CONTROLLED DRUG RELEASE; CORNEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; HEAT SENSITIVITY; HUMAN; HYDROGEL; NONHUMAN; PH; PHASE TRANSITION; REVIEW; UVEITIS;

EID: 67149123505     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v26.i1.30     Document Type: Review

References (140)

1. Hecht G. Ophthalmic preparations. In: Gennaro AR, editor. Remington: The science and practice of pharmacy. Easton (PA): Mack Publishing Co.; 2000. p. 821-35.
2. Olejnik O. Conventional systems in ophthalmic drug delivery. In: Mitra AK, editor. Ophthalmic drug delivery systems. New York: Marcel Dekker Inc.; 1993. p. 177-98.
3. Saettone MF. Progress and problems in ophthalmic drug delivery. Business Briefing Pharmatech. 2002:1-6.
4. Poland DE, Kaufman HE. Clinical uses of collagen shields. J Cataract Refract Surg. 1988; 14:489-91.
5. Bloomfield SE, Miyata T, Dunn MW, Bueser N, Stenzel KH, Rubin AL. Soluble gentamicin ophthalmic inserts as a drug delivery system. Arch Ophthalmol Vis Sci. 1978;34:2581-7.
6. Punch PI, Costa ND, Edwards ME, Wilcox GE. The release of insoluble antibiotics from collagen ocular inserts in vitro and their insertion into the conjunctival sac of cattle. J Vet Pharmacol Ther. 1987;10:37-42.
7. Lee VHL. Mechanisms and facilitation of corneal drug penetration. J Control Release. 1990;11:79-90.
8. Kaufman HE. Collagen shield symposium. J Cataract Refract Surg. 1988;14:487-8.
9. Sintzel MB, Bernatchez SF, Tatabay C, Gurny R. Biomaterials in ophthalmic drug delivery. Eur J Pharm Biopharm. 1996;42:358-74.
10. Sawusch MR, O'Brien TP, Dick JD, Gottsch JD. Use of collagen corneal shields in the treatment of bacterial keratitis. Am J Ophthalmol. 1988;106:279-81.
11. Lee BL, Matoba AY, Osato MS, Robinson NM. The solubility of antibiotic and corticosteroid combinations. Am J Ophthalmol. 1992;114:212-5.
12. Kaufman HE, Steinemann TL, Lehman E, Thompson HW, Varnell ED, LaBarre J, Gebhardt BM. Collagen-based drug delivery and artificial tears. J Ocul Pharmacol. 1994;10:17-27.
13. Kunou N, Ogura Y, Hashizoe M, Honda Y, Hyon SH, Ikada Y. Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. J Control Release. 1995;37:143-50.
14. Jalil RU. Biodegradable poly (Lactic acid) and poly (Lactide-Co- Glycolide) polymers in sustained drug delivery. Drug Dev Ind Pharm. 1990;16:2353-67.
15. Hashizoe M, Ogura Y, Kimura H, Moritera T, Honda Y, Kyo M, Hyon S, Ikada Y. Scleral plug of biodegradable polymers for controlled drug release in the vitreous. Arch Ophthalmol. 1994;112:1380-4.
16. Kimura H, Ogura Y, Hashizoe M, Nishiwaki H, Honda Y, Ikada Y. A new vitreal drug delivery system using an implantable biodegradable polymeric device. Invest Ophthalmol Vis Sci. 1994;35:2815-9.
17. Sanborn GE, Anand R, Torti RE, Nightingale SD, Cal SX, Yates B, Ashton P, Smith T. Sustained-release gancyclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol. 1992;110:188-95.
18. Saettone MF, Salimen L. Ocular inserts for topical delivery. Adv Drug Deliv Rev. 1995;16:95-106.
19. Saettone MF. Solid polymeric inserts/disks as drug delivery devices. In: Edman P, editor. Biopharmaceutics of ocular drug delivery. Boca Raton (FL): CRC Press; 1993. p. 61-80.
20. Lele BS, Hoffman AS. Insoluble ionic complexes of polyacrylic acid with a cationic drug for use as a mucoadhesive, ophthalmic drug delivery system. J Biomater Sci Polym Ed 2000;11:1319-31.
21. Kawakami S, Nishida K, Mukai T, Yamamura K, Nakamura J, Sakaeda T, Nakashima M, Sasaki H. Controlled release and ocular absorption of tilisolol utilizing ophthalmic insert-incorporated lipophilic prodrugs. J Control Release. 2001;76:255-63.
22. Mundada AS, Shrikhande BK. Formulation and evaluation of cip- rofloxacin hydrochloride soluble ocular drug insert. Curr Eye Res. 2008;33:469-75.
23. Di Colo G, Burgalassi S, Chetoni P, Fiaschi MP, Zambito Y, Saettone MF. Relevance of polymer molecular weight to the in vitro/in vivo performances of ocular inserts based on poly(ethylene oxide). Int J Pharm. 2001;220:169-77.
24. Kreuter J. Nanoparticles as bioadhesive ocular drug delivery systems. In: Lenaerts V, Gurny R, editors. Bioadhesive drug delivery systems. Boca Raton (FL): CRC Press; 1990. p. 203-12.
25. Zimmer AK, Kreuter J, Robinson JR. Studies on the transport pathway of PBCA nanoparticles in ocular tissues. J Microencapsul. 1991;8:497-504.
26. Hui HW, Robinson JR. Ocular delivery of progesterone using a bioadhesive polymer. Int J Pharm. 1985;26:203-13.
27. Park K, Robinson JR. Bioadhesive polymers as platform for oral controlled drug delivery: method to study bioadhesion. Int J Pharmacol. 1984;191:107-10.
28. Lee VHL. Precorneal, corneal and postcorneal factors. In: Mitra AK, editor. Ophthalmic drug delivery systems. New York: Marcel Dekker Inc.; 1993. p. 59-82.
29. Liaw J, Robinson JR. Ocular penetration enhancers. Mitra AK, editor. Ophthalmic drug delivery systems. New York: Marcel Dekker Inc.; 1993. p. 369-82.
30. Saettone MF, Chetoni P, Cerbai R, Mazzanti G, Braghiroli L. Evaluation of ocular permeation enhancers: in vitro effects on corneal transport of four β-blockers, and in vitro/in vivo toxic activity. Int J Pharm. 1996;142:103-13.
31. van der Bijl P, van Eyk AD, Meyer D. Effects of three penetration enhancers on transcorneal permeation of cyclosporine. Cornea. 2001;20:505-8.
32. Burgalassi S, Chetoni P, Monti D, Saettone MF. Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines. Toxicol Let. 2001;122:1-8.
33. Green K, Chapman JM, Cheeks JL. Ocular penetration of pilocarpine in rabbits. J Toxicol. 1987;2:89-107.
34. Merkus FWHM, Schipper NGM, Hermens WAJJ, Romeijn SG, Verhoef JC. Absorption enhancers in nasal drug delivery: efficacy and safety. J Control Release. 1993;24:201-8.
35. Grass JM, Robinson JR. Relationship of chemical structure to corneal penetration and influence of low viscosity solution on ocular bioavailability. J Pharm Sci. 1984;73:1021-7.
36. Durrani M, Davies NM, Thomas M, Kellaway IW. Pilocarpine bio- availability from a mucoadhesive liposomal ophthalmic drug delivery system. Int J Pharm. 1992;88:409-15.
37. Davies NM, Farr SJ, Hadgraft J, Kellaway IW. Evaluation of mucoad- hesive polymers in ocular drug delivery: II. Polymer coated vesicles. Pharm Res. 1992;9:1137-44.
38. Pleyer U, Elkins B, Rückert D, Lutz S, Grammer J, Chou J, Schmidt KH, Mondino BJ. Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields. Curr Eye Res. 1994;13:177-81.
39. Kaur IP, Kanwar M. Ocular preparations: The formulation approach. Drug Dev Ind Pharm. 2002;28:473-93.
40. Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P. Poly(e- caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm Res. 1993;10:386-90.
41. Calvo P, Thomas C, Alonso MJ, Vila-Jato J, Robinson JR. Study of the mechanism of interaction of poly(e-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy. Int J Pharm. 1994;103:283-91.
42. Marchal-Heussler L, Fessi H, Devissaguet JP, Hoffman M, Maincent P. Bioadhesive liposomes as topical drug delivery systems: molecular and cellular studies. STP Pharma Sci. 1992;2:98-104.
43. Rincón Alarcón A, Molina Martinez IT. Intraocular drug delivery systems. Arch Soc Esp Oftalmol. 2006;81:57-60.
44. Maurice DM. Kinetics of topically applied drugs. In: Saettone MF, Bucci P, Speiser P, editors. Ophthalmic drug delivery, biopharmaceuti- cal, technological and clinical aspects. Fidia Research Series, Vol. II. Padova, Italy: Liviana Press; 1987. p. 19-26.
45. Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974;63:333-8.
46. Lee VH, Robinson JR. Topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol. 1986;2:67-108.
47. Watsky MA, Jablonski MM, Edelhauser HF. Comparison of conjunc- tival and corneal surface areas in rabbit and human. Curr Eye Res. 1988;7:483-6.
48. Kogbe O, Liotet S. Modification of rabbit conjunctiva following instillation of commonly used ophthalmic drugs. STP Pharm Sci. 1992;2:39-44.
49. Huang AJW, Tseng SCG, Kenyon KR. Paracellular permeability of corneal and conjunctival epithelia. Invest Ophthalmol Vis Sci. 1989;30:684-9.
50. Desai SD, Blanchard J. In: Swarbick J, Boylan JC, editors. Encyclopedia of Pharmaceutical Technology, vol. 11. New York: Marcel Dekker Inc.; 1994. p. 43-75.
51. Meseguer G, Gurny R, Buri P. In vivo evaluation of dosage forms: application of gamma scintigraphy to non-enteral routes of administration. J Drug Target. 1994;2:269-88.
52. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87:1479-88.
53. Liaw J, Rojanasakul Y, Robinson JR. The effect of drug charge type and charge density on cornea1 transport. Int J Pharm. l992;88:111-24.
54. Ahmed I, Gokhlae RD, Shah MV, Patton TF. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. J Pharm Sci. 1987;76:583-6.
55. Ashton P, Podder SK, Lee VH. Formulation influence on conjunctival penetration of four beta blockers in the pigmented rabbit: a comparison with corneal penetration. Pharm Res. 1991;8:1166-74.
56. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability: Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36:1893-1903.
57. Edwards A, Prausnitz MR. Fiber matrix model of sclera and corneal stroma for drug delivery to the eye. AIChE J. 1998;44:214-225.
58. Romanelli L, Valeri P, Morrone LA, Pimpinella G, Graziani G, Tita B. Ocular absorption and distribution of bendazac after topical administration to rabbits with different vehicles. Life Sci. 1994;54:877-85.
59. Hosoya K, Lee VH. Cidofovir transport in the pigmented rabbit conjunctiva. Curr Eye Res. 1997;16:693-7.
60. Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems-recent advances. Prog Retin Eye Res. 1998;17:33-58.
61. Felt O, Baeyens V, Zignani M, Buri P, Gurny R. Mucosal drug delivery- ocular. In: Encyclopedia of controlled drug delivery, vol. 2. Geneva, Switzerland: University of Geneva; 1999. p. 605-622.
62. Le Bourlais CA, Treupel-Acar L, Rhodes CT, Sado PA, Leverge R. New ophthalmic drug delivery systems. Drug Dev Ind Pharm. 1995;21:19-59.
63. Peppas NA, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm. 2000;50:27-46.
64. Soppimath KS, Aminabhavi TM, Dave AM, Kumbar SG, Rudzinski WE. Stimulus-responsive "smart" hydrogels as novel drug delivery systems. Drug Dev Ind Pharm. 2002;28: 957-74.
65. Gurny R, Ibrahim H, Buri P. The development and use of in situ formed gels, triggered by pH. In: Edman P, editor. Biopharmaceutics of ocular drug delivery. Boca Raton (FL): CRC Press; 1993. p. 81-90.
66. Miller SC, Donovan MD. Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits. Int J Pharm. 1982;12:147-52.
67. Gurny R, Boye T, Ibrahim H. Ocular therapy with nanoparticulate systems for controlled drug delivery. J Control Release. 1985;2:353-61.
68. Moorhouse R, Colegrove GT, Sandford PA, Baird JK, Kang KS. PS-60: A new gel forming polysaccharide. In: Brant DA, editor. Solution properties of polysaccharides. Washington (DC): American Chemical Society, ACS Symposium Series; 1981. p. 111-24.
69. Huffman AS, Afrassiabi A, Dong LC. Thermally reversible hydrogels: II. Delivery and selective removal of substances from aqueous solutions. J Control Release. 1986;4:213-22.
70. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev. 2001;53:321-39.
71. Heskins M; Guillet JE. Solution properties of poly(N-Isopropylacryl- amide). J Macromol Sci Chem. 1968;A2:1441-55.
72. Cao Y, Zhang C, Shen W, Cheng Z, Yu LL, Ping Q. Poly(N- isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery. J Control Release. 2007;120:186-94.
73. Bromberg LE, Ron ES. Temperature responsive gels and thermogel- ling polymer matrices for protein and peptide delivery. Adv Drug Deliv Rev. 1998;31:197-221.
74. Miyazaki S, Suisha F, Kawasaki A, Shirakawa M, Yamatoya K, Attwood D. Thermally reversible xyloglucan gels as vehicles for rectal drug delivery. J Control Release. 1998;56:75-83.
75. Cabana A, Ait-Kadi A, Juhasz J. Study of the gelation process of polyethylene oxidea- polypropylene oxideb- polyethylene oxidea copolymer (poloxamer 407) aqueous solutions. J Colloid Interface Sci. 1997;190:307-12.
76. Ruel-Gariepy E, Leroux JC. In situ-forming hydrogels-review of temperature-sensitive systems. Eur J Pharm Biopharm. 2004;58:409-26.
77. Miller SC, Drabic BR. Rheological properties of poloxamer vehicles. Int J Pharm. 1984;18:269-76.
78. Waring GO, Harris RR. Symposium on ocular therapy. New York: Wiley; 1979. p. 127-40.
79. Edsman K, Carlfors J, Petersson R. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci. 1998;6:105-12.
80. El-Kamel AH. In vitro and in vivo evaluation of Pluronic F127- based ocular delivery system for timolol maleate. Int J Pharm. 2002;241:47-55.
81. Wei G, Xu H, Ding PT, Li SM, Zheng JM. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J Control Release. 2002;83:65-74.
82. Lin HR, Sung KC, Vong WJ. In situ gelling of alginate/pluronic solutions for ophthalmic delivery of pilocarpine. Biomacromolecules. 2004;5:2358-65.
83. Lin HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Release. 2000;69:379-88.
84. Qi H, Chen W, Huang C, Li L, Chen C, Li W, Wu C. Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int J Pharm. 2007;337:178-87.
85. Mansour M, Mansour S, Mortada ND, Abd Elhady SS. Ocular polox- amer-based ciprofloxacin hydrochloride in situ forming gels. Drug Dev Ind Pharm. 2008;34:744-52.
86. Gilbert JC, Hadgraft J, Bye A, Brookes LG. Drug release from Pluronic F-127 gels. Int J Pharm. 1986;32:223-8.
87. Yoo MK, Cho KY, Song HH, Choi YJ, Kwon JW, Kim MK, Lee JH, Wee WR, Cho CS. Release of ciprofloxacin from chondroitin 6-sulfate- graft-poloxamer hydrogel in vitro for ophthalmic drug delivery. Drug Dev Ind Pharm. 2005;31:455-63.
88. Ma WD, Xu H, Nie SF, Pan WS. Temperature-responsive, Pluronic-g- poly(acrylic acid) copolymers in situ gels for ophthalmic drug delivery: rheology, in vitro drug release and in vivo resident property. Drug Dev Ind Pharm. 2008;34:258-66.
89. Ma WD, Xu H, Wang C, Nie SF, Pan WS. Pluronic F127-g-poly(acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system. Int J Pharm. 2008;350:247-56.
90. Fry SC. The structure and functions of xyloglucan. J Exp Bot. 1989;40:1-11.
91. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev. 2005;57:1595-639.
92. Burgalassi S, Raimondi L, Pirisino R, Banchelli G, Boldrini E, Saettone MF. Effect of xyloglucan (tamarind seed polysaccharide) on conjunctival cell adhesion to laminin and on corneal epithelium wound healing. Eur J Ophthalmol. 2000;10:71-6.
93. Burgalassi S, Chetoni P, Panichi L, Boldrini E, Saettone MF. Xyloglucan as a novel vehicle for timolol: pharmacokinetics and pressure lowering activity in rabbits. J Ocul Pharmacol Ther. 2000;16:497-509.
94. Raimondi L, Sgromo L, Banchelli G, Corti I, Pirisino R, Boldrini E. A new viscosity enhancer for ophthalmic preparations devoid of toxicity for human conjunctival cells. J Toxicol: Cutan Ocul Toxicol. 2000;19:31-42.
95. Shirakawa M, Yamatoya K, Nishinari K. Tailoring xyloglucan properties using an enzyme. Food Hydrocolloids. 1998;12:25-8.
96. Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm. 2001;229:29-36.
97. Harrington WF, Von Hippel PH. The structure of collagen and gelatin. Adv Protein Chem. 1961;16:1-138.
98. Carlsson A, Karlstrom G, Lindman B, Stenberg O. Interaction between ethyl (hydroxyethyl) cellulose and sodium dodecyl sulphate in aqueous solution. Colloid Polym Sci. 1988;266:1031-36.
99. Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery: a review. J Control Release. 2007;122:119-34.
100. Sultana Y, Aqil M, Ali A, Zafar S. Evaluation of carbopol-methyl cellulose based sustained-release ocular delivery system for pefloxacin mesylate using rabbit eye model. Pharm Dev Technol. 2006;11:313-9.
101. Peppas LB, Peppas NA. Solute and penetrant diffusion in swellable polymer. IX. The mechanism of drug release from pH-sensitive swelling- controlled systems. J Control Release. 1989;8:267-74.
102. Bettini R, Colombo P, Peppas NA. Solubility effect on drug transport through pH-controlled release systems: Transport of theophyl- line and metoclopramide monohydrochloride. J Control Release. 1995;37:105-11.
103. Secard DL. Carbopol pharmaceuticals. Drug Cosmet Ind. 1962;90:28-30, 113, 115-116.
104. McGinity JW, Harris MR, Patel K, Davis SS. Carbomer. In: Handbook of pharmaceutical excipients. London: The Pharmaceutical Society of Great Britain; 1986. p. 41-2.
105. Leung SS, Robinson JR. The contribution of anionic polymer structural features to mucoadhesion. J Control Release. 1988;5:223-31.
106. Davies NM, Farr SJ, Hadgraft J, Kellaway IW. Evaluation of mucoad- hesive polymers in ocular drug delivery. I. Viscous solutions. Pharm Res. 1991;8:1039-43.
107. Chrai SS, Robinson JR. Ocular evaluation of methylcellulose vehicle in albino rabbits. J Pharm Sci. 1974;63:1218-23.
108. Saettone MF, Giannaccini B, Guiducci A, Savigni P. Semisolid ophthalmic vehicles. III. An evaluation of four organic hydrogels containing pilocarpine. Int J Pharm. 1986;31:261-70.
109. Kumar S, Haglund BO, Himmelstein KJ. In situ-forming gels for ophthalmic drug delivery. J Ocul Pharmacol. 1994;10:47-56.
110. Kumar S, Himmelstein KJ. Modification of in situ gelling behavior of carbopol solutions by hydroxypropyl methylcellulose. J Pharm Sci. 1995;84:344-8.
111. Wu C, Qi H, Chen W, Huang C, Su C, Li W, Hou S. Preparation and evaluation of a Carbopol/HPMC-based in situ gelling ophthalmic system for puerarin. Yakugaku Zasshi. 2007;127:183-91.
112. Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release. 2001;73:205-11.
113. Bhaskaran S, Lakshmi PK, Harish CG. Topical ocular drug delivery-a review. Ind J Pharm Sci. 2005;67:404-8.
114. Deasy PB, Quigley KJ. Rheological evaluation of deacetylated gellan gum (Gelrite) for pharmaceutical use. Int J Pharm. 1991;73:117-23.
115. Jansson PE, Lindberg B, Sandford PA. Structural studies of gellan gum, an extracellular polysaccharide elaborated by Pseudomonas elo- dea. Carbohydrate Res. 1983;124:135-9.
116. Kuo MS, Mort AJ, Dell A. Identification and location of L-glycerate, an unusual acyl substituent in gellan gum. Carbohydrate Res. 1986;156:173-87.
117. Morris VJ. Bacterial polysaccharides. In: Stephen AM, editor. Food polysaccharides and their application. New York: Marcel Dekker Inc.; 1995. p. 341-75.
118. Rozier A, Mazuel C, Grove J, Plazonnet B. Gelrite®: A novel, ion- activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharm. 1989;57:163-8.
119. Robinson G, Manning CE, Morris ER. Conformation and physical properties of the bacterial polysaccharides gellan, welan and rhamsan. In: Dickinson E, editor. Food polymers, gels, and colloids. London: Royal Society of Chemistry; 1991.
120. Kang KS, Veeder GT, Mirrasoul PJ, Kaneko T, Cottrell IW. Agar-like polysaccharide produced by a Pseudomonas species: Production and basic properties. Appl Environ Microbiol. 1982;43:1086-91.
121. Maurice DM, Srinivas SP. Use of fluorometry in assessing the efficacy of a cation- sensitive gel as an ophthalmic vehicle: Comparison with scintigraphy. J Pharm Sci. 1992;81:615-8.
122. Meseguer G, Gurny R, Buri P, Rozier A, Plazonnet B. Gamma scinti- graphic study of precorneal drainage and assessment of miotic response in rabbits of various ophthalmic formulations containing pilocarpine. Int J Pharm. 1993;95:229-34.
123. Ramaiah S, Pramod Kumar TM, Valluru R. Studies on biopolymers for ophthalmic drug delivery. J Macromol Sci Part A. 2007;44:229-34.
124. Balasubramaniam J, Kant S, Pandit JK. In vitro and in vivo evaluation of the Gelrite gellan gum-based ocular delivery system for indometha- cin. Acta Pharm. 2003;53:251-61.
125. Balasubramaniam J, Pandit JK. Ion-activated in situ gelling systems for sustained ophthalmic delivery of ciprofloxacin hydrochloride. Drug Deliv. 2003;10:185-91.
126. Sultana Y, Aqil M, Ali A. Ion-activated, Gelrite-based in situ ophthalmic gels of pefloxacin mesylate: comparison with conventional eye drops. Drug Deliv. 2006;13:215-9.
127. Haug A, Larsen B, Smidsr0d O. A study of the constitution of alginic acid by partial hydrolysis. Acta Chem Scand. 1966;20:183-90.
128. Painter TJ, Smidsr0d O, Haug A. A computer study of the changes in composition-distribution occurring during random depolymeri- sation of a binary linear heteropolysaccharide. Acta Chem Scand. 1968;22:1637-48.
129. Larsen B, Smidsr0d O, Painter TJ, Haug A. Calculation of the nearest-neighbour frequencies in fragments of alginate from the yields of free monomers after partial hydrolysis. Acta Chem Scand. 1970;24:726-8.
130. Cohen S, Lobel E, Trevgoda A, Peled Y. A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J Control Release. 1997;44:201-8.
131. Liu Z, Li J, Nie S, Liu H, Ding P, Pan W. Study of an alginate/HPMC- based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm. 2006;315:12-7.
132. Liu Z, Yang XG, Li X, Pan W, Li J. Study on the ocular pharmacokinet- ics of ion-activated in situ gelling ophthalmic delivery system for gatifloxacin by microdialysis. Drug Dev Ind Pharm. 2007;33:1327-31.
133. Karkelle M, Brunstedt MR. Carragenan viscoelastics for ocular surgery. U.S. Patent 2004;0019010A1.
134. Robinson JR, Mlynek GM. Bioadhesive and phase-change polymers for ocular drug delivery. Adv Drug Deliv Rev. 1995;16:45-50.
135. Gupta H, Jain S, Mathur R, Mishra P, Mishra AK, Velpandian T. Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv. 2007;14:507-15.
136. Ooteghem M. Formulations of ophthalmic solutions and suspensions. Problems and advantages. In: P. Edman, editor. Biopharmaceutics of ocular drug delivery. Boca Raton (FL): CRC Press; 1993. p. 27-42.
137. Bron AJ, Mengher LS. The ocular surface in keratoconjunctivitis sicca. Eye. 1989;3:428-37.
138. Greaves JL, Wilson CG, Rozier A, Grove J, Plazonnet B. Scintigraphic assessment of an ophthalmic gelling vehicle in man and rabbit. Curr Eye Res. 1990;9:415-20.
139. Gurny R, Ibrahim H, Aehi A, Burl P, Wilson CG, Washington N, Edman P, Camber O. Design and evaluation of controlled release systems for the eye. In: Anderson JM, Kim SW, editors. Advances in drug delivery systems. Amsterdam: Elsevier; 1987. p. 367-73.
140. Saettone MF, Chetoni P, Torracca MT, Burgalassi S, Giannaccini B. Evaluation of muco-adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid. Int J Pharm. 1989;51:203-12.